Infectious Disease Market Size to grow by USD 104.81 billion between 2023-2027
According to a research report “ Infectious Disease Market” by Product (Drugs, Vaccines) End-user (Hospital, Multispecialty clinic, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 104.81 billion, at a CAGR of 12.49% during the forecast period. The global infectious disease landscape is experiencing a significant shift, with an increasing prevalence of diseases caused by organisms such as bacteria, viruses, fungi, and parasites. Factors contributing to this trend include changing lifestyles and the emergence of drug-resistant pathogens. HIV/AIDS remains a leading cause of death, with 680,000 fatalities reported in 2020, according to UNAIDS data. However, there have also been notable decreases in the incidence of certain infectious diseases, such as meningococcal disease in the US. It is imperative for businesses to stay informed of these trends and adapt accordingly to mitigate potential risks and ensure the health and safety of their workforce and customer base.
Browse market data tables, figures, and in-depth TOC on “Infectious Disease Market” by Product (Drugs, Vaccines) End-user (Hospital, Multispecialty clinic, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample
By Product, the Drugs segment is projected to dominate the market size in 2024
The hospital sector is poised for substantial growth in the global infectious disease market, driven by the rising caseload of patients afflicted with various infectious diseases, including HIV/AIDS, tuberculosis, meningitis, and COVID-19. The burgeoning demand for infectious disease diagnostics is fueled by this increasing patient population. In developed markets, such as the US, the favorable reimbursement landscape bolsters the adoption of diagnostic solutions. For instance, the US Department of Health and Human Services (HHS) allocated USD25 billion in September 2021 to address COVID-19 testing and vaccination efforts. This significant investment underscores the market potential for infectious disease diagnostics.
By End-user, Hospital segment is expected to hold the largest market size for the year 2024
The Infectious Disease Market is experiencing significant growth due to several key drivers. Notably, increasing initiatives by governments and non-profit organizations to raise awareness about infectious diseases are fueling market expansion. Additionally, the escalating prevalence of diseases such as common cold, giardiasis, HIV/AIDS, mononucleosis, and influenza is anticipated to boost market growth. According to the World Health Organization (WHO), approximately 1.5 million new HIV infections are projected in 2020, with a significant proportion occurring in low and middle-income countries like India, Brazil, and Sub-Saharan Africa, where an estimated 66% of those infected reside. The increasing funding for research and development (R&D) in this sector is also contributing to market growth.
North America is forecasted to hold the largest market size by region in 2024
The Infectious Disease Market in North America is predominantly driven by the United States due to the presence of leading players such as Gilead Sciences, Johnson & Johnson, Pfizer, and AbbVie. These companies generate substantial revenue from their market-leading drugs and invest heavily in marketing and patient awareness initiatives. The US contributes significantly to the infectious disease market in the region, with key players including Aridis Pharmaceuticals, Entasis Therapeutics, and Merck. Factors fueling market expansion include the introduction of novel drugs for infectious disease treatment and the prioritization of proper patient care. The market is projected to experience robust growth throughout the forecast period.
The Infectious Disease Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Title: Advancements in Infectious Disease Diagnostics: RNA Viruses, PoC Testing, and Beyond The global infectious disease market is witnessing significant growth due to the increasing prevalence of diseases such as RNA viruses, gonorrhea, syphilis, and mosquito-borne diseases like Hepatitis A, B, and C. Traditional laboratory testing methods, including DNA microarray and Next-Generation Sequencing (NGS), have revolutionized disease diagnosis, enabling faster and more accurate results. Clinical microbiology, immunodiagnostics, and healthcare professionals are at the forefront of this transformation. Training and education are crucial to ensure the effective implementation of these advanced diagnostic tools. Poor water sanitation, inadequate infrastructure, and hygiene remain significant challenges in the fight against infectious diseases. Point-of-care (PoC) testing, such as rapid DNA sequencing and immunodiagnostics, is increasingly being used in ambulances, emergency rooms, and urgent care centers to provide prompt diagnosis and rapid results. Personal health and infection control are essential for positive patient outcomes. As the world continues to grapple with infectious diseases, advancements in diagnostics will play a pivotal role in ensuring effective treatment and disease management.
Market Research Overview
The Infectious Disease Market encompasses a wide range of diagnostic tests and technologies used for the detection and diagnosis of various communicable diseases, including mosquito-borne diseases, sexually transmitted inctions (STIs) such as syphilis, HPV, Neisseria gonorrhea, and Chlamydia trachomatis, hospital-acquired infections (HAIs), tuberculosis (TB), HIV hepatitis, and non-notifiable infections. PoC testing plays a crucial role in this market, enabling prompt diagnosis and rapid results in various settings, from physician offices to emergency rooms. Centralised laboratories and hospitals also utilize advanced technologies like proteomics and genomics for personalised medicines and DNA microarray, next-generation sequencing (NGS), and DNA sequencing for identifying pathogens. Insurance companies and preventative healthcare initiatives drive the demand for diagnostic tests, addressing lifestyle disorders and the geriatric population. Hospitalisation rate for infectious diseases is a significant concern, with tuberculosis, hepatitis, gonorrhea, and HIV being leading causes for hospitalizations. Diagnostic tests include laboratory tests like PCR testing, immunodiagnostics, and clinical microbiology, as well as physical exams, CT scans, chest X-rays, and various kits and reagents for blood and respiratory secretions. Major pathogens include parasites, fungi, viruses, and bacteria, with respiratory infections and diseases being a significant application area. Technologies like amplification technology, isothermal nucleic acid amplification, and RT-PCR are essential for diagnosing RNA viruses like SARS-CoV-2, Influenza, and hepatitis C. Healthcare professionals require ongoing training to effectively use these technologies and maintain infection control to improve patient outcomes. Factors like poor water sanitation, inadequate infrastructure, and hygiene contribute to the spread of infectious diseases. Ambulances, emergency rooms, and urgent care centres play a vital role in addressing these issues by providing prompt diagnosis and care. The market for infectious disease diagnostics is continuously evolving, with ongoing research and development in various technologies and applications.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
